Anti SMARCA2 pAb (ATL-HPA029981)

Atlas

Catalog No: ATL-HPA029981-25

• 
• 

Protein Description: SWI/SNF related, matrix associated, actin dependent regulator of chromatin, subfamily a, member 2
Gene Name: SMARCA2
Alternative Gene Name: BAF190, BRM, hBRM, hSNF2a, SNF2, SNF2L2, SNF2LA, Sth1p, SWI2
Isotype: IgG
Interspecies mouse/rat: ENSMUSG00000024921: 82%, ENSRNOG00000011931: 81%
Entrez Gene ID: 6595
Uniprot ID: P51531
Buffer: 40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative.
Storage Temperature: Store at +4°C for short term storage. Long time storage is recommended at -20°C.

Product Specifications

• Application: ICC, IHC
• Reactivity: Human
• Clonality: Polyclonal
• Host: Rabbit
• Immunogen: SPVQLHQLRAQILAYKMLARGQPLPETLQLAVQGKRTLPGLQQQQQQQQQQQQQQQQQQQQQQQPQQQPPQPQTQQQQQPALVNYNRPSGPGPELSGPSTPQKLPVP
• Gene Sequence: SPVQLHQLRAQILAYKMLARGQPLPETLQLAVQGKRTLPGLQQQQQQQQQQQQQQQQQQQQQQQPQQQPPQPQTQQQQQPALVNYNRPSGPGPELSGPSTPQKLPVP
• Gene ID - Mouse: ENSMUSG00000024921
• Gene ID - Rat: ENSRNOG00000011931
• Buffer: 40% glycerol and PBS (pH 7.2). 0.02% sodium azide is added as preservative.

Citations for Anti SMARCA2 pAb (ATL-HPA029981) – 12 Found

Jiang, Wei; Dulaimi, Essel; Devarajan, Karthik; Parsons, Theodore; Wang, Qiong; O'Neill, Raymond; Solomides, Charalambos; Peiper, Stephen C; Testa, Joseph R; Uzzo, Robert; Yang, Haifeng. Intratumoral heterogeneity analysis reveals hidden associations between protein expression losses and patient survival in clear cell renal cell carcinoma. Oncotarget. 2017;8(23):37423-37434. 

Naito, Tomoyuki; Umemura, Shigeki; Nakamura, Hiroshi; Zenke, Yoshitaka; Udagawa, Hibiki; Kirita, Keisuke; Matsumoto, Shingo; Yoh, Kiyotaka; Niho, Seiji; Motoi, Noriko; Aokage, Keijyu; Tsuboi, Masahiro; Ishii, Genichiro; Goto, Koichi. Successful treatment with nivolumab for SMARCA4-deficient non-small cell lung carcinoma with a high tumor mutation burden: A case report. Thoracic Cancer. 2019;10(5):1285-1288. 

Ehrenhöfer-Wölfer, Katharina; Puchner, Teresa; Schwarz, Cornelia; Rippka, Janine; Blaha-Ostermann, Silvia; Strobl, Ursula; Hörmann, Alexandra; Bader, Gerd; Kornigg, Stefan; Zahn, Stephan; Sommergruber, Wolfgang; Schweifer, Norbert; Zichner, Thomas; Schlattl, Andreas; Neumüller, Ralph A; Shi, Junwei; Vakoc, Christopher R; Kögl, Manfred; Petronczki, Mark; Kraut, Norbert; Pearson, Mark A; Wöhrle, Simon. SMARCA2-deficiency confers sensitivity to targeted inhibition of SMARCA4 in esophageal squamous cell carcinoma cell lines. Scientific Reports. 2019;9(1):11661. 

Van Houdt, Jeroen K J; Nowakowska, Beata Anna; Sousa, Sérgio B; van Schaik, Barbera D C; Seuntjens, Eve; Avonce, Nelson; Sifrim, Alejandro; Abdul-Rahman, Omar A; van den Boogaard, Marie-José H; Bottani, Armand; Castori, Marco; Cormier-Daire, Valérie; Deardorff, Matthew A; Filges, Isabel; Fryer, Alan; Fryns, Jean-Pierre; Gana, Simone; Garavelli, Livia; Gillessen-Kaesbach, Gabriele; Hall, Bryan D; Horn, Denise; Huylebroeck, Danny; Klapecki, Jakub; Krajewska-Walasek, Malgorzata; Kuechler, Alma; Lines, Matthew A; Maas, Saskia; Macdermot, Kay D; McKee, Shane; Magee, Alex; de Man, Stella A; Moreau, Yves; Morice-Picard, Fanny; Obersztyn, Ewa; Pilch, Jacek; Rosser, Elizabeth; Shannon, Nora; Stolte-Dijkstra, Irene; Van Dijck, Patrick; Vilain, Catheline; Vogels, Annick; Wakeling, Emma; Wieczorek, Dagmar; Wilson, Louise; Zuffardi, Orsetta; van Kampen, Antoine H C; Devriendt, Koenraad; Hennekam, Raoul; Vermeesch, Joris Robert. Heterozygous missense mutations in SMARCA2 cause Nicolaides-Baraitser syndrome. Nature Genetics. 2012;44(4):445-9, S1. 

Karnezis, Anthony N; Wang, Yemin; Ramos, Pilar; Hendricks, William Pd; Oliva, Esther; D'Angelo, Emanuela; Prat, Jaime; Nucci, Marisa R; Nielsen, Torsten O; Chow, Christine; Leung, Samuel; Kommoss, Friedrich; Kommoss, Stefan; Silva, Annacarolina; Ronnett, Brigitte M; Rabban, Joseph T; Bowtell, David D; Weissman, Bernard E; Trent, Jeffrey M; Gilks, C Blake; Huntsman, David G. Dual loss of the SWI/SNF complex ATPases SMARCA4/BRG1 and SMARCA2/BRM is highly sensitive and specific for small cell carcinoma of the ovary, hypercalcaemic type. The Journal Of Pathology. 2016;238(3):389-400. 

Jelinic, Petar; Schlappe, Brooke A; Conlon, Niamh; Tseng, Jill; Olvera, Narciso; Dao, Fanny; Mueller, Jennifer J; Hussein, Yaser; Soslow, Robert A; Levine, Douglas A. Concomitant loss of SMARCA2 and SMARCA4 expression in small cell carcinoma of the ovary, hypercalcemic type. Modern Pathology : An Official Journal Of The United States And Canadian Academy Of Pathology, Inc. 2016;29(1):60-6. 

Jiang, Wei; Dulaimi, Essel; Devarajan, Karthik; Parsons, Theodore; Wang, Qiong; Liao, Lili; Cho, Eun-Ah; O'Neill, Raymond; Solomides, Charalambos; Peiper, Stephen C; Testa, Joseph R; Uzzo, Robert; Yang, Haifeng. Immunohistochemistry Successfully Uncovers Intratumoral Heterogeneity and Widespread Co-Losses of Chromatin Regulators in Clear Cell Renal Cell Carcinoma. Plos One. 11(10):e0164554. 

Huang, Shih-Chiang; Ng, Kwai-Fong; Chang, Ian Yi-Feng; Chang, Chee-Jen; Chao, Yi-Chun; Chang, Shu-Chen; Chen, Min-Chi; Yeh, Ta-Sen; Chen, Tse-Ching. The clinicopathological significance of SWI/SNF alterations in gastric cancer is associated with the molecular subtypes. Plos One. 16(1):e0245356. 

Armon, Subasri; Hofman, Paul; Ilié, Marius. Perspectives and Issues in the Assessment of SMARCA4 Deficiency in the Management of Lung Cancer Patients. Cells. 2021;10(8) 

Kofink, Christiane; Trainor, Nicole; Mair, Barbara; Wöhrle, Simon; Wurm, Melanie; Mischerikow, Nikolai; Roy, Michael J; Bader, Gerd; Greb, Peter; Garavel, Géraldine; Diers, Emelyne; McLennan, Ross; Whitworth, Claire; Vetma, Vesna; Rumpel, Klaus; Scharnweber, Maximilian; Fuchs, Julian E; Gerstberger, Thomas; Cui, Yunhai; Gremel, Gabriela; Chetta, Paolo; Hopf, Stefan; Budano, Nicole; Rinnenthal, Joerg; Gmaschitz, Gerhard; Mayer, Moriz; Koegl, Manfred; Ciulli, Alessio; Weinstabl, Harald; Farnaby, William. A selective and orally bioavailable VHL-recruiting PROTAC achieves SMARCA2 degradation in vivo. Nature Communications. 2022;13(1):5969. 

Cantley, Jennifer; Ye, Xiaofen; Rousseau, Emma; Januario, Tom; Hamman, Brian D; Rose, Christopher M; Cheung, Tommy K; Hinkle, Trent; Soto, Leofal; Quinn, Connor; Harbin, Alicia; Bortolon, Elizabeth; Chen, Xin; Haskell, Roy; Lin, Eva; Yu, Shang-Fan; Del Rosario, Geoff; Chan, Emily; Dunlap, Debra; Koeppen, Hartmut; Martin, Scott; Merchant, Mark; Grimmer, Matt; Broccatelli, Fabio; Wang, Jing; Pizzano, Jennifer; Dragovich, Peter S; Berlin, Michael; Yauch, Robert L. Selective PROTAC-mediated degradation of SMARCA2 is efficacious in SMARCA4 mutant cancers. Nature Communications. 2022;13(1):6814. 

Bharathy, Narendra; Cleary, Megan M; Kim, Jin-Ah; Nagamori, Kiyo; Crawford, Kenneth A; Wang, Eric; Saha, Debarya; Settelmeyer, Teagan P; Purohit, Reshma; Skopelitis, Damianos; Chang, Kenneth; Doran, Jessica A; Kirschbaum, C Ward; Bharathy, Suriya; Crews, Davis W; Randolph, Matthew E; Karnezis, Anthony N; Hudson-Price, Lisa; Dhawan, Jyotsna; Michalek, Joel E; Ciulli, Alessio; Vakoc, Christopher R; Keller, Charles. SMARCA4 biology in alveolar rhabdomyosarcoma. Oncogene. 2022;41(11):1647-1656.